Our

Pipeline

Our Pipeline Includes Potential First- Or
Best-In-Class Molecules

Cullinan Oncology has built a diversified pipeline by identifying high-impact targets first and then pursuing the right modality. The pipeline contains assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be best- or first-in-class.
pipeline-best-in-class
Image of Circles

Programs Spanning A Range Of Indications And Platforms.

Zipalertinib (CLN-081/TAS6417)

EGFRex20ins inhibitor in collaboration with Taiho Pharmaceutical, Inc.
Phase 2
 
NSCLC with exon 20 insertion mutations
Status:
BTD received; actively enrolling Phase 2b
CLN-049
FLT3 x CD3 bispecific
Phase 1
 
R/R AML, MDS
Status:
Actively enrolling

CLN-619

Anti-MICA/B IgG1
Phase 1
 
Pan-cancer
Status:
Actively enrolling

CLN-617

Collagen-binding IL-12-IL2 fusion protein
IND-Enabling
 
Pan-cancer
Status:
IND-enabling studies

CLN-978

CD19/CD3 T-cell antibody construct with HSA binding domain
IND-Enabling
 
B-cell NHL
Status:
IND-enabling studies

Early Programs

Powered by our novel research model and with patient benefit as our priority, we innovate without borders, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. Early programs we're currently exploring include:
  • T-cell Receptor (TCR) – TCR-based therapy targeting a senescence and cancer-related protein pMHC complex.
  • HPK1 Targeting – A potential first-in-class protein degrader that acts as a negative regulator of T cells and TCR signaling.
 
 

Our Differentiated Oncology Assets

By identifying high-impact targets, then pursuing the right modality, we've built a diversified pipeline of assets ranging from engineered proteins to monoclonal antibodies, as well as kinase inhibitors and protein degraders, each with the potential to be best or first in its class.
 

Harnessing Science for Patient Benefit

Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.